Page 6 - Director Redmile Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director redmile group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Redmile Group Today - Breaking & Trending Today

Fate Therapeutics (NASDAQ:FATE) Given New $5.00 Price Target at Stifel Nicolaus

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price objective cut by Stifel Nicolaus from $5.30 to $5.00 in a report issued on Thursday morning, The Fly reports. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating and reduced their […] ....

United States , David Scadden , Scott Wolchko , Leonard Zon , Stifel Nicolaus , Michael Rudnicki , Alexander Rives , Rudolf Jaenisch , Philip Beachy , Managers Group , Fate Therapeutics Company Profile , Fate Therapeutics Inc , Redmile Group Llc , Coppell Advisory Solutions Corp , Ci Investments Inc , Nisa Investment Advisors , Fate Therapeutics , Get Rating , Therapeutics Stock Down , Director Redmile Group , Investment Advisors , Coppell Advisory Solutions , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Fate Therapeutics (NASDAQ:FATE) Price Target Cut to $5.00 by Analysts at Cantor Fitzgerald

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […] ....

Philip Beachy , Leonard Zon , Rudolf Jaenisch , David Scadden , Alexander Rives , Scott Wolchko , Michael Rudnicki , Morgan Stanley , Nisa Investment Advisors , Coppell Advisory Solutions Corp , Ci Investments Inc , Fate Therapeutics Inc , Cantor Fitzgerald , Managers Group , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Investment Advisors , Coppell Advisory Solutions , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Analysts Set Expectations for Fate Therapeutics, Inc.'s Q4 2024 Earnings (NASDAQ:FATE)

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at SVB Leerink issued their Q4 2024 earnings per share estimates for Fate Therapeutics in a research report issued on Thursday, May 4th. SVB Leerink analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. SVB Leerink […] ....

Philip Beachy , Alexander Rives , Scott Wolchko , Michael Rudnicki , Rudolf Jaenisch , David Scadden , Leonard Zon , Fate Therapeutics Inc , Redmile Group Llc , Fate Therapeutics Company Profile , Cantor Fitzgerald , Financial Services Group Inc , Royal Bank , Wells Fargo Company , Fate Therapeutics , Get Rating , Fate Therapeutic , Truist Financial , Therapeutics Trading Down , Pension Plan Investment Board , Services Group , Two Sigma Advisers , Sigma Advisers , Director Redmile Group , Sheng Ding , Fate Therapeutics Daily ,

Fate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Estimates By $0.36 EPS

Fate Therapeutics (NASDAQ:FATE – Get Rating) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The firm had […] ....

United States , Alexander Rives , Rudolf Jaenisch , Philip Beachy , Stifel Nicolaus , Leonard Zon , David Scadden , Scott Wolchko , Michael Rudnicki , Vanguard Group Inc , Fate Therapeutics Inc , Pricet Rowe Associates Inc , Fate Therapeutics Company Profile , Redmile Group Llc , Blackrock Inc , Wells Fargo Company , Fate Therapeutics , Get Rating , Therapeutics Stock Down , Director Redmile Group , Street Corp , Capital World Investors , World Investors , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate ,

Gamble Jones Investment Counsel Decreases Stock Position in NextEra Energy, Inc. (NYSE:NEE)

Fate Therapeutics (NASDAQ:FATE – Get Rating) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. The firm had revenue of $58.98 million during the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a […] ....

United States , David Scadden , Michael Rudnicki , Scott Wolchko , Philip Beachy , Leonard Zon , Alexander Rives , Rudolf Jaenisch , Envestnet Asset Management Inc , Financial Services Group Inc , Securities Exchange Commission , Raymond James Associates , Ef Hutton Acquisition Co , Redmile Group Llc , Advisor Group , Fate Therapeutics Inc , Hightower Advisors , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Asset Management , Tower Advisors , Services Group , Truist Financial , Sheng Ding ,